PROfound trial
PROfound Trial: OS Improvement With Olaparib in Subset of Patients With mCRPC
In men with metastatic castration-resistant prostate cancer and mutations in genes associated with homologous ...
MARCH 3, 2021
Lynparza Approved for Use in HRR-Mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...
MAY 28, 2020
Load more